Literature DB >> 25742673

Analysis of research ethics board approval times in an academic department of medicine.

Teresa S M Tsang1, Meaghan Jones2, Graydon S Meneilly2.   

Abstract

As part of an ongoing effort to better understand barriers to academic research, we reviewed and analyzed the process of research ethics applications, focusing on ethics approval time, within the Department of Medicine from 2006 to 2011. A total of 1,268 applications for approval to use human subjects in research were included in our analysis. Three variables, risk category (minimal vs. non-minimal risk), type of funding, and year of submission, were statistically significant for prediction of ethics approval time, with risk status being the most important of these. The covariate-adjusted mean time for approval for minimal risk studies (35.7 days) was less than half that of non-minimal risk protocols (76.5 days). Studies funded through a for-profit sponsor had significantly longer approval times than those funded through other means but were also predominantly (87%) non-minimal risk protocols. Further investigations of the reasons underlying the observed differences are needed to determine whether improved training for research ethics board (REB) members and/or greater dialogue with investigators may reduce the lengthy approval times associated with non-minimal risk protocols.
© The Author(s) 2015.

Entities:  

Keywords:  human subjects research; institutional review boards; research ethics; research ethics boards

Mesh:

Year:  2015        PMID: 25742673     DOI: 10.1177/1556264615571557

Source DB:  PubMed          Journal:  J Empir Res Hum Res Ethics        ISSN: 1556-2646            Impact factor:   1.742


  1 in total

1.  Time required to review research protocols at 10 Veterans Affairs Institutional Review Boards.

Authors:  Patrick R Varley; Ulrike Feske; Shasha Gao; Roslyn A Stone; Sijian Zhang; Robert Monte; Robert M Arnold; Daniel E Hall
Journal:  J Surg Res       Date:  2016-06-08       Impact factor: 2.192

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.